CONTEXT: Eosinophilic renal neoplasms include a spectrum of solid and papillary tumors ranging from indolent benign oncocytoma to highly aggressive malignancies.
Recognition of the correct nature of the tumor, especially in biopsy specimens, is paramount for patient management.
OBJECTIVE: To review the diagnostic approach to eosinophilic renal neoplasms with light microscopy and ancillary techniques.
DATA SOURCES: Review of the published literature and personal experience.
CONCLUSIONS: The following tumors are in the differential diagnosis of oncocytic renal cell neoplasm: oncocytoma, chromophobe renal cell carcinoma (RCC), hybrid tumor, tubulocystic carcinoma, papillary RCC, clear cell RCC with predominant eosinophilic cell morphology, follicular thyroid-like RCC, hereditary leiomyomatosis-associated RCC, acquired cystic disease-associated RCC, rhabdoid RCC, microphthalmia transcription factor translocation RCC, epithelioid angiomyolipoma, and unclassified RCC. In low-grade nonpapillary eosinophilic neoplasms, distinction between oncocytoma and low-grade RCC mostly rests on histomorphology; however, cytokeratin 7 immunostain may be helpful. In high-grade nonpapillary lesions, there is more of a role for ancillary techniques, including immunohistochemistry for cytokeratin 7, CA9, CD10, racemase, HMB45, and Melan-A. In papillary eosinophilic neoplasms, it is important to distinguish sporadic type 2 papillary RCC from microphthalmia transcription factor translocation and hereditary leiomyomatosis-associated RCC. Histologic and cytologic features along with immunohistochemistry and fluorescence in situ hybridization tests for TFE3 (Xp11.2) and TFEB [t(6;11)] are reliable confirmatory tests. Eosinophilic epithelial neoplasms with architecture, cytology, and/or immunoprofile not qualifying for either of the established types of RCC should be classified as unclassified eosinophilic RCC and arbitrarily assigned a grade (low or high).
Written by:
Kryvenko ON, Jorda M, Argani P, Epstein JI. Are you the author?
Departments of Pathology and Urology, University of Miami Miller School of Medicine, Miami, Florida; and the Departments of Pathology, Oncology, and Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.
Reference: Arch Pathol Lab Med. 2014 Nov;138(11):1531-41
doi: 10.5858/arpa.2013-0653-RA
PubMed Abstract
PMID: 25357116